Follow us on Twitter
twitter icon@FreshPatents


Factor patents

      

This page is updated frequently with new Factor-related patent applications.




new patent Discovery resource time-frequency hopping method and terminal
Embodiments of the present invention disclose a discovery resource time-frequency hopping method and a terminal, where the terminal includes: a resource determining unit, configured to determine a real discovery resource in a real discovery resource pool; a frequency-domain expansion unit, configured to: perform frequency-domain virtual expansion on the real discovery resource pool according to a frequency division multiplexing factor value, and determine a virtual discovery resource in a virtual discovery resource pool corresponding to the real discovery resource pool; a time-frequency hopping unit, configured to perform, according to a time-frequency hopping solution, virtual time-frequency hopping on a correspondence between the terminal and the determined virtual discovery resource in the virtual discovery resource pool; and a signal sending unit, configured to send a discovery signal by using a real discovery resource that corresponds to a virtual discovery resource which is occupied after the virtual time-frequency hopping.. .
Huawei Technologies Co., Ltd.


new patent Computerized back surgery prediction system and method
A computerized back surgery predictive model identifies a risk population for back surgery and assigns a severity level to members of the risk population. High risk members are informed of preference-sensitive surgeries and alternative treatment options.
Humana Inc.


new patent Personal digital identity card with motion sensor responsive to user interaction
A personal digital id device provides a digital identifier to a service for a predetermined duration in response to user interaction. The user interaction may include a button press.
Tyfone, Inc.


new patent Configurable personal digital identity card with motion sensor responsive to user interaction
A personal digital id device provides a digital identifier to a service for a predetermined duration in response to user interaction. The user interaction may include a button press.
Tyfone, Inc.


new patent Induction of hemogenic endothelium from pluripotent stem cells
Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hpscs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hpscs of a combination of transcription factors as described herein.. .
Wisconsin Alumni Research Foundation


new patent Defined three dimensional microenvironment for cell culture
This disclosure provides a three-dimensional (3d) microenvironment presenting defined biochemical and physical cues that regulate cellular behavior and use of the microenvironment. A composition to form the 3d microenvironment is provided by combining one or more natural or synthetic polymeric materials and substrate proteins recombinantly or chemically functionalized with a variety of bioactive peptides such as extracellular matrix-derived or growth factor-derived peptides.
Kollodis Biosciences, Inc.


new patent Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
The present invention relates to a vhh which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.. .
Universiteit Twente


new patent Recombinant factor viii proteins
Provided are recombinant factor viii proteins, e.g., human factor viii proteins with heterologous moieties inserted into flexible permissive loops located in the factor viii a domains, while retaining the procoagulant activity of factor viii.. .
Biogen Idec Ma Inc.


new patent Novel modified curcumins and their uses
Wherein α, β, a, b, and r1-r4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (mmp), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting nfκ-b activation in a population of cells..

new patent Small molecule inhibitors of dusp6 and uses therefor
Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


new patent

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

This document relates to conjugates of tnf inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.. .
Quiapeg Pharmaceuticals Ab

new patent

Materials and methods for the development of an antigen-specific immune non-responsiveness state

The present invention provides materials and methods for making a subject non-responsive to an antigen. Methods of the invention may comprise contacting the subject with the antigen and a compound that induces anergy.
A&g Pharmaceutical, Inc

new patent

Antidotes for factor xa inhibitors and methods of using the same

The present invention relates antidotes to anticoagulants targeting factor xa. The antidotes are factor xa protein derivatives that bind to the factor xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex.
Portola Pharmaceuticals, Inc.

new patent

Non-surgical, localized delivery of compositions for placental growth factors

Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery..
Mimedx Group, Inc.

Raw camera peripheral with handheld mobile unit for processing raw image data

A handheld imaging device is described to provide high quality raw image data to a smartphone, or similar handheld imaging device. The imaging device can have a larger dimension, particularly with regard to the thickness of the device, thus overcoming some of the physical limitations to providing high quality optics and image sensing within the thin form factor of a modern smartphone.
2p & M Holdings, Llc

Raw camera peripheral with handheld mobile unit processing raw image data

A handheld imaging device is described to provide high quality raw image data to a smartphone, or similar handheld imaging device. The imaging device can have a larger dimension, particularly with regard to the thickness of the device, thus overcoming some of the physical limitations to providing high quality optics and image sensing within the thin form factor of a modern smartphone.
2p & M Holdings, Llc

Raw camera peripheral for handheld mobile unit

A handheld imaging device is described to provide high quality raw image data to a smartphone, or similar handheld imaging device. The imaging device can have a larger dimension, particularly with regard to the thickness of the device, thus overcoming some of the physical limitations to providing high quality optics and image sensing within the thin form factor of a modern smartphone.
2p & M Holdings, Llc

Apparatus and supporting an article

Modular mounting systems for supportably engagement of one or more devices. The systems may include corresponding attachment members and carrier members for selective supportive engagement of one or more devices relative to a base.
Iomounts Llc

Identification of ports from which cables have been recently removed and that have the same physical form factor using existing visual port indicators

An electronic device has a number of ports that have the same physical form factor and that are receptive to cable insertion. The electronic device also has visual indicators corresponding to the ports.
Lenovo Enterprise Solutions (singapore) Pte. Ltd.

Method and processing adaptive interrupt, host employing the same, i/o device and system

Processing an adaptive interrupt includes selectively setting an input/output (i/o) device in a computing system to an adaptive masking mode when at least one factor value of the at least one i/o device regarding a workload of the computing system exceeds a first threshold condition. Processing the adaptive interrupt further includes performing an interrupt masking process, where an interrupts generated by an i/o device set to the adaptive masking mode are prevented from being output when a time interval between i/o submission events of the i/o device is less than a first threshold value.

Dna encoding ring zinc-finger protein and the use of the dna in vectors and bacteria and in plants

The present inventions relate to compositions and methods for providing stress tolerant transgenic plants comprising a ring domain zinc-finger motif transcription factor protein. More particularly, the invention relates to compositions and methods comprising a ring-h2 domain transcription factor protein for providing drought and salt tolerant plants, in particular comprising a recombinant xerico gene and protein..
Board Of Trustees Of Michigan State University

Compositions and methods for activating silent gene clusters

The disclosure provides compositions and methods for producing natural products in microorganisms that are otherwise unexpressed, poorly expressed or poorly transcribed. In particular aspects, the disclosure provides compositions and methods for activating a silent gene or gene cluster with a bacteriophage and/or streptomyces antibiotic regulatory protein (sarp) transcription factor..
Radiant Genomics, Inc.

The usage of odontogenic stem cells and genetically modified odontogenic stem cells

Provided in the present invention are odontogenic stem cells and a use of genetically modified odontogenic stem cells for treating periodontal disease, repairing defects in periodontal bone tissues or soft tissues and/or promoting the regeneration of periodontal tissues, or in products for treating acute and chronic bone tissue injuries (e.g. Bone fracture) or bone tissue defects.
Beijing Sh Bio-tech Corporation

Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool

Provided are a system and methods for selectively inducing expansion of a population of t cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of ctls, preferably human ctls.
The Trustees Of The University Of Pennsylvania

Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases

The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a gsk3 inhibitor and a tgf-β inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates.
Biolamina Ab

Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human c1 esterase inhibitor or factor xii. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema..
Cornell University

Process for producing and purifying factor viii and its derivatives

Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.

Nucleotide sequence and pharmaceutical composition based thereon with prolonged vegf transgene expression

A nucleic acid or transgene comprising a modified vegf 3′-untranslated region (3′-utr) polynucleotide sequence and a polynucleotide sequence encoding a vascular endothelial growth factor (vegf). When transformed into a host cell, the nucleic acid or transgene exhibits a high stability and provides prolonged and reliable expression of vegf.
"nextgen" Company Limited

Factor xia inhibitors

The present invention provides a compound of formula (i) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective factor xia inhibitors or dual inhibitors of factor xia and plasma kallikrein..
Merck Sharp & Dohme Corp.

Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to fusion proteins comprising an epidermal growth factor receptor variant iii (egfrviii) polypeptide and a mesothelin polypeptide, and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
Aduro Biotech, Inc.

Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof

The present invention relates to prophylactic dosing regimens with long-acting factor ix (fix) in dosing intervals of 1 week or longer, including (but not limited to) 10 days or longer, such as two weeks, three weeks or even monthly.. .
Csl Limited

Factor ix polypeptides and methods of use thereof

The present invention provides methods of administering factor ix; methods of administering chimeric and hybrid polypeptides comprising factor ix; chimeric and hybrid polypeptides comprising factor ix; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
Biogen Hemophilia Inc.

Method to induce neovascular formation and tissue regeneration

The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (vegf), or that encodes a polypeptide comprising an active site of the vegf. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte.
Fundacion Universitaria Dr. Rene G. Favaloro

Lid for container

A lid for a container is described. The lid has a basin that is designed to enhance the user's olfactory experience when drinking a beverage from the container and lid.
Harl-bella Holdings, Llc

Methods for testing anti-thrombotic agents

The invention provides a transgenic non-human animal expressing von willebrand factor a1 protein containing at least one mutation selected from the group consisting of: 1263p>s, 1269n>d, 1274k>r, 1287m>r, 1302g>d, 1308h>r, 1313r>w, 1314i>v, 1326r>h, 1329l>i, 1330e>g, 1333a>d, 1344t>a, 1347i>v, 1350t>a, 1370g>s, 1379h>r, 1381t>a, 1385t>m 1391p>q, 1394a>s, 1397l>f, 1421s>n, 1439l>v, 1442g>s, 1449r>q, 1466a>p, 1469q>l, 1472q>h, 1473v>m, 1475h>q, 1479s>g, and any combination thereof.. .
The Trustees Of Columbia University In The City Of New York

Compositions and methods for quantitative assessment of dna-protein complex density

One aspect of the present invention describes materials and methods of quantitatively measuring the density or percent occupancy of dna binding proteins such as histones, histone variants, histone post translational modifications and transcription factors in chromatin at given dna loci. One embodiment measures a factor's average quantity at specific gene loci, and controls for a number of pitfalls concerning antibody quality and handling issues.
The University Of Chicago

Method of identifying tyrosine kinase receptor rearrangements in patients

The present invention provides a method of characterizing a cancer by obtaining a sample from a subject suspected of having cancer; and determining whether a fibroblast growth factor receptor (fgfr) fusion is present in the sample, wherein the fgfr fusion comprises a fgfr locus, thereby characterizing the cancer based on the presence or absence of the fgfr fusion.. .
Translational Genomics Research Institute

Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf

Oligonucleotide compounds modulate expression and/or function of vascular endothelial growth factor (vegf) polynucleotides and encoded products thereof. Methods for treating diseases associated with vascular endothelial growth factor (vegf) comprise administering one or more oligonucleotide compounds designed to inhibit the vegf natural antisense transcript to patients..
Curna, Inc.

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance.
The Johns Hopkins University

A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag

A process for manufacturing of a factor viii product having a ratio of fviii:c/fviii:ag of at least 0.7 in the factor viii product by using chromatography wherein at least one chromatographic step is performed by means of employing; an affinity chromatography resin having an affinity for specifically binding of factor viii which is effected by an affinity ligand which is immobilised on the affinity chromatography resin, said affinity ligand is a 13 kd yeast derived fab antibody fragment directed to the factor viii molecule. An anionic chromatography resin.
Octapharma Ag

Dihydropyridone p1 as factor xia inhibitors

Or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.

Methods for treating cancer and non-neoplastic conditions

Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (vegf) and compositions comprising such compounds are described. Compounds that inhibit viral replication or the production of viral rna or dna or viral protein and compositions comprising such compounds are described.
Ptc Therapeutics, Inc.

Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Which possess inhibitory activity against activating mutant forms of egfr, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man..

Factor xia inhibitors

The present invention provides a compound of formula (i) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective factor xia inhibitors or dual inhibitors of factor xia and plasma kallikrein..
Merck Sharp & Dohme Corp.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3389

file didn't exist3035

469979 - 0 - 61